Drugs / VELUFENACIN
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT05992428 | Aug → Nov 2023 | — | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05991401 | Aug → Nov 2023 | — | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05812417 | May 2023 → Jun 2024 | impaired renal function disease | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04686825 | Jan → Feb 2021 | — | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03566134 | Jul 2018 → Dec 2019 | overactive bladder | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05282069 | May 2022 → Nov 2023 | overactive bladder | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02821312 Comparator | Jun 2016 → Jan 2017 | overactive bladder | Dong-A ST Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VELUFENACIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL5810614 ↗ |
| Known as | DA-8010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02821312 ↗ |
| Modality | Small molecule | — CHEMBL5810614 ↗ |
| Route | Oral | “Multiple Oral Administration of DA-8010” NCT02821312 ↗ |